BACKGROUND: High-dose oral vitamin D (stoss) is a novel treatment in children with inflammatory bowel disease (IBD). Vitamin D supplementation may have benefits in IBD beyond bone health including reduced disease activity and improvements in inflammatory markers. The aim of this study was to retrospectively assess the efficacy, safety and impact on disease activity of single oral high-dose vitamin D3 therapy in New Zealand (NZ) children with IBD and vitamin D deficiency. METHODS: In this retrospective chart review, children with IBD and vitamin D deficiency [serum 25-OH vitamin D level (25-OHD) <50 nmol/L] in Christchurch, NZ, who were managed with single high-dose vitamin D3 therapy were identified. Measurements of serum 25-OHD, calcium and standard serum inflammatory markers prior to and up to 6 months following stoss therapy were extracted from patient records. Disease activity was also defined using the Pediatric Crohn's Disease (CD) Activity Index (PCDAI) at time points before and 3 months following stoss. RESULTS: Twenty-eight doses of stoss were given to 23 children, aged 3-16 years. Mean 25-OHD levels increased after stoss therapy from 39 nmol/L (95% CI: 37-42 nmol/L) at baseline to 189 nmol/L (148-231 nmol/L) at 1-2 months (P<0.001). All children with 1 month levels measured achieved 25-OHD >75 nmol/L. One child had a serum calcium of 2.7 (normal range, 2.2 to 2.6 mmol/L) 2 weeks after treatment, which normalized on repeat testing 10 days later. PCDAI scores, mean platelet count, erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) all reduced significantly from baseline to 3 months following stoss therapy. CONCLUSIONS: Single high-dose oral vitamin D therapy was used successfully and safely to manage vitamin D deficiency in these children with IBD. An improvement in inflammatory markers and disease activity scores also occurred following stoss therapy.
BACKGROUND: High-dose oral vitamin D (stoss) is a novel treatment in children with inflammatory bowel disease (IBD). Vitamin D supplementation may have benefits in IBD beyond bone health including reduced disease activity and improvements in inflammatory markers. The aim of this study was to retrospectively assess the efficacy, safety and impact on disease activity of single oral high-dose vitamin D3 therapy in New Zealand (NZ) children with IBD and vitamin D deficiency. METHODS: In this retrospective chart review, children with IBD and vitamin D deficiency [serum 25-OH vitamin D level (25-OHD) <50 nmol/L] in Christchurch, NZ, who were managed with single high-dose vitamin D3 therapy were identified. Measurements of serum 25-OHD, calcium and standard serum inflammatory markers prior to and up to 6 months following stoss therapy were extracted from patient records. Disease activity was also defined using the Pediatric Crohn's Disease (CD) Activity Index (PCDAI) at time points before and 3 months following stoss. RESULTS: Twenty-eight doses of stoss were given to 23 children, aged 3-16 years. Mean 25-OHD levels increased after stoss therapy from 39 nmol/L (95% CI: 37-42 nmol/L) at baseline to 189 nmol/L (148-231 nmol/L) at 1-2 months (P<0.001). All children with 1 month levels measured achieved 25-OHD >75 nmol/L. One child had a serum calcium of 2.7 (normal range, 2.2 to 2.6 mmol/L) 2 weeks after treatment, which normalized on repeat testing 10 days later. PCDAI scores, mean platelet count, erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) all reduced significantly from baseline to 3 months following stoss therapy. CONCLUSIONS: Single high-dose oral vitamin D therapy was used successfully and safely to manage vitamin D deficiency in these children with IBD. An improvement in inflammatory markers and disease activity scores also occurred following stoss therapy.
Authors: James D Lewis; Faten N Aberra; Gary R Lichtenstein; Warren B Bilker; Colleen Brensinger; Brian L Strom Journal: Gastroenterology Date: 2004-03 Impact factor: 22.682
Authors: Lisa A Houghton; Ewa A Szymlek-Gay; Andrew R Gray; Elaine L Ferguson; Xiaolan Deng; Anne-Louise M Heath Journal: Am J Clin Nutr Date: 2010-05-19 Impact factor: 7.045
Authors: Richard B Gearry; Ann Richardson; Christopher M A Frampton; Judith A Collett; Michael J Burt; Bruce A Chapman; Murray L Barclay Journal: Inflamm Bowel Dis Date: 2006-10 Impact factor: 5.325
Authors: Philip T Liu; Steffen Stenger; Huiying Li; Linda Wenzel; Belinda H Tan; Stephan R Krutzik; Maria Teresa Ochoa; Jürgen Schauber; Kent Wu; Christoph Meinken; Diane L Kamen; Manfred Wagner; Robert Bals; Andreas Steinmeyer; Ulrich Zügel; Richard L Gallo; David Eisenberg; Martin Hewison; Bruce W Hollis; John S Adams; Barry R Bloom; Robert L Modlin Journal: Science Date: 2006-02-23 Impact factor: 47.728
Authors: Reinhold Vieth; Heike Bischoff-Ferrari; Barbara J Boucher; Bess Dawson-Hughes; Cedric F Garland; Robert P Heaney; Michael F Holick; Bruce W Hollis; Christel Lamberg-Allardt; John J McGrath; Anthony W Norman; Robert Scragg; Susan J Whiting; Walter C Willett; Armin Zittermann Journal: Am J Clin Nutr Date: 2007-03 Impact factor: 7.045
Authors: Jennifer E Rockell; Timothy J Green; C Murray Skeaff; Susan J Whiting; Rachael W Taylor; Sheila M Williams; Winsome R Parnell; Robert Scragg; Noela Wilson; David Schaaf; Eljon D Fitzgerald; Mark W Wohlers Journal: J Nutr Date: 2005-11 Impact factor: 4.798
Authors: J S Hyams; G D Ferry; F S Mandel; J D Gryboski; P M Kibort; B S Kirschner; A M Griffiths; A J Katz; R J Grand; J T Boyle Journal: J Pediatr Gastroenterol Nutr Date: 1991-05 Impact factor: 2.839
Authors: A Aratari; C Papi; B Galletti; E Angelucci; A Viscido; V D'Ovidio; A Ciaco; M Abdullahi; R Caprilli Journal: Dig Liver Dis Date: 2005-11-10 Impact factor: 4.088